Back to search results

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

IsraelRecruitingPHASE1, PHASE2

Conditions

Carcinoma, Non-Small-Cell Lung

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States

  • City of Hope ( Site 0014), Duarte, California, United States

  • UCSF Medical Center at Mission Bay ( Site 0007), San Francisco, California, United States

  • Georgetown University ( Site 0036), Washington D.C., District of Columbia, United States

  • University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky, United States

  • MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States

  • Massachusetts General Hospital ( Site 0003), Boston, Massachusetts, United States

  • Dana Farber Cancer Institute ( Site 0002), Boston, Massachusetts, United States

  • Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha, Nebraska, United States

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon, New Hampshire, United States

    Study coordinator · 603-650-4428

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037), Hackensack, New Jersey, United States

  • Laura and Isaac Perlmutter Cancer Center ( Site 0034), New York, New York, United States

  • Sanford Fargo Medical Center ( Site 0039), Fargo, North Dakota, United States

    Study coordinator · 701-234-2000

  • Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus, Ohio, United States

    Study coordinator · 614-366-0233

  • Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States

    Study coordinator · 215-220-9703

  • Sanford Cancer Center ( Site 0038), Sioux Falls, South Dakota, United States

    Study coordinator · 605-328-8000

  • The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas, United States

    Study coordinator · 713-792-6363

  • Petz Aladar Megyei Oktato Korhaz ( Site 0062), Győr, Győr-Moson-Sopron, Hungary

  • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061), Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Orszagos Koranyi Pulmonologiai Intezet ( Site 0060), Budapest, Hungary

  • Soroka Medical Center ( Site 0072), Beersheba, Israel

  • Rambam Health Care Campus-Oncology ( Site 0076), Haifa, Israel

  • Shaare Zedek Medical Center ( Site 0075), Jerusalem, Israel

    Study coordinator · +97225645203

  • Meir Medical Center ( Site 0071), Kfar Saba, Israel

  • Rabin Medical Center ( Site 0074), Petah Tikva, Israel

  • Chaim Sheba Medical Center ( Site 0070), Ramat Gan, Israel

    Study coordinator · +97235307096

  • Sourasky Medical Center ( Site 0077), Tel Aviv, Israel

  • Azienda Ospedaliera Universitaria Careggi ( Site 0173), Florence, Firenze, Italy

  • IRCCS Ospedale San Raffaele ( Site 0171), Milan, Italy

  • Policlinico Gemelli di Roma ( Site 0174), Roma, Italy

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0151), Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150), Gdansk, Pomeranian Voivodeship, Poland

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152), Koszalin, West Pomeranian Voivodeship, Poland

  • Seoul National University Bundang Hospital ( Site 0081), Seongnam-si, Kyonggi-do, South Korea

  • Severance Hospital ( Site 0080), Seoul, South Korea

  • Samsung Medical Center ( Site 0082), Seoul, South Korea

  • ICO L Hospitalet ( Site 0090), L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Quiron Madrid ( Site 0091), Madrid, Spain

  • Changhua Christian Hospital ( Site 0181), Changhua, Taiwan

    Study coordinator · +886983901629

  • Taipei Medical University Hospital ( Site 0180), Taipei, Taiwan

    Study coordinator · +886227372181x7810

  • Chang Gung Medical Foundation-Linkou Branch ( Site 0182), Taoyuan, Taiwan

    Study coordinator · +886975368109

  • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0463), Cherkasy, Cherkasy Oblast, Ukraine

    Study coordinator · +380472370123

  • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0460), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

    Study coordinator · +380978411455

  • ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 0461), Rivne, Rivne Oblast, Ukraine

    Study coordinator · +380362633075

  • Uzhhorod Multispecialty City Clinical Hospital ( Site 0462), Uzhhorod, Zakarpattia Oblast, Ukraine

    Study coordinator · +380506847086
Study leads

  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)